Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde, Desiree   •   Cheng-Chung Wei, James   •   Dougados, Maxime   •   Mease, Philip   •   Deodhar, Atul   •   Maksymowych, Walter P   •   Van den Bosch, Filip   •   Sieper, Joachim   •   Tomita, Tetsuya   •   Landewe, Robert   •   Zhao, Fangyi   •   Krishnan, Eswar   •   Adams, David H   •   Pangallo, Beth   •   Carlier, Hilde

published in: Lancet (London, England)



endpoint

Ixekizumab has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1016/S0140-6736(18)31946-9
pubmed
30360964
2018
Journal Article
randomized controlled trial
yes
prospective
1+